Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 6:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Muscular Disorders, Atrophic Clear all
Not yet recruiting Early Phase 1 Interventional

Metformin and ACLR Muscle Recovery

NCT07699367
View directory record Official record
Conditions
Atrophy, Inflammation, Weakness, Muscle
Interventions
Metformin, Placebo
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 22, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

NCT00467844
View directory record Official record
Conditions
Cachexia
Interventions
GTx-024, Placebo
Drug
Lead sponsor
GTx
Industry
Eligibility
Not listed
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
50
States / cities
Anchorage, Alaska • Fayetteville, Arkansas • Corona, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Sep 22, 2026, 6:55 PM EDT
Completed Not applicable Interventional

BFRT for Severe Lower Extremity Muscle Atrophy

NCT04357184
View directory record Official record
Conditions
Severe Muscle Atrophy, Muscle Weakness
Interventions
Blood flow restriction training
Other
Lead sponsor
Cincinnati Sportsmedicine Research and Education Foundation
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Sep 22, 2026, 6:55 PM EDT
Completed Phase 1 Interventional

Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy

NCT00374075
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Valproic Acid
Drug
Lead sponsor
University of Utah
Other
Eligibility
2 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Sep 22, 2026, 6:55 PM EDT
Completed Phase 3 Interventional

A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD)

NCT00018109
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
glutamine, creatine monohydrate
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
5 Years to 10 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 22, 2026, 6:55 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Evaluation of the Healthy Lifestyle Program on Cognitive Outcomes

NCT03926481
View directory record Official record
Conditions
Obesity
Interventions
Evaluate Healthy Lifestyle Program on cognitive outcomes
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
65 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Sep 22, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)

NCT00303446
View directory record Official record
Conditions
Kennedy's Disease, Spinal and Bulbar Muscular Atrophy
Interventions
Dutasteride, Placebo
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2011 · Synced Sep 22, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy

NCT00227266
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Valproic Acid and Levocarnitine, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
2 Years to 17 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Baltimore, Maryland • Detroit, Michigan • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 22, 2026, 6:55 PM EDT
Completed Not applicable Interventional Results available

Glutathione and Health With Post-Polio Syndrome

NCT01402570
View directory record Official record
Conditions
Post-polio Syndrome, Physical Activity, Depression, Pain, Sleep Disorders
Interventions
Glutathione
Dietary Supplement
Lead sponsor
University of Michigan
Other
Eligibility
50 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Sep 22, 2026, 6:55 PM EDT
Terminated Not applicable Interventional Results available

Blood Flow Restriction Therapy Following Acute Shoulder Injury Patients

NCT06223373
View directory record Official record
Conditions
Shoulder Injury
Interventions
Blood Flow Restriction, "sham" Blood Flow Restriction
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 22, 2026, 6:55 PM EDT
Recruiting No phase listed Observational

DMD Voice: Qualitative Interviews With Patients and Caregivers

NCT06925269
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
Not listed
Lead sponsor
Red Nucleus Enterprise Solutions, LLC
Industry
Eligibility
10 Years and older · Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Yardley, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 22, 2026, 6:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Protein Blends on Muscle Protein Synthesis in Healthy Older Adults

NCT01847261
View directory record Official record
Conditions
Muscle Synthesis
Interventions
Soy Dairy Protein Blend, Positive Control (Dairy Whey Protein)
Dietary Supplement
Lead sponsor
DuPont Nutrition and Health
Industry
Eligibility
55 Years to 70 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2019 · Synced Sep 22, 2026, 6:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Role of MicroRNAs on Age and Contraction-induced Skeletal Muscle Growth

NCT02638454
View directory record Official record
Conditions
Sarcopenia
Interventions
Acute Resistance Exercise
Procedure
Lead sponsor
Tufts University
Other
Eligibility
20 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 22, 2026, 6:55 PM EDT
Terminated Phase 2 Interventional Results available

Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities

NCT04572893
View directory record Official record
Conditions
Primary Familial Dilated Cardiomyopathy
Interventions
danicamtiv
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
12
States / cities
La Jolla, California • Washington D.C., District of Columbia • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 22, 2026, 6:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Functional Assessment and Muscle Evaluation Through Exercise Trial

NCT03166150
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Multi-modal rehabilitation program, Pelvic Floor Physical therapy
Other
Lead sponsor
Howard University
Other
Eligibility
65 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Sep 22, 2026, 6:55 PM EDT
Completed No phase listed Observational

Cardiac Outcome Measures in Children With Muscular Dystrophy

NCT01066455
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Limb Girdle Muscular Dystrophy
Interventions
Not listed
Lead sponsor
Cooperative International Neuromuscular Research Group
Network
Eligibility
8 Years to 18 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Sacramento, California • Washington D.C., District of Columbia • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Sep 22, 2026, 6:55 PM EDT
Recruiting Phase 2 Interventional

Essential Amino Acid Supplementation for Femoral Fragility Fractures

NCT06050668
View directory record Official record
Conditions
Femoral Fracture, Fragility Fracture, Muscle Atrophy
Interventions
Essential Amino Acid Supplementation
Combination Product
Lead sponsor
Michael C Willey
Other
Eligibility
65 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Iowa City, Iowa • Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 22, 2026, 6:55 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of PS-IPC Supplementation on Muscle Mass and Functional Outcomes in Older Adults

NCT00926250
View directory record Official record
Conditions
Immune Senescence, Sarcopenia
Interventions
Oral PS-IPC supplement, Placebo supplement
Dietary Supplement
Lead sponsor
University of Arkansas
Other
Eligibility
60 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2012 · Synced Sep 22, 2026, 6:55 PM EDT
Completed Phase 1 Interventional

An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)

NCT02052791
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
nusinersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Sep 22, 2026, 6:55 PM EDT
Recruiting Phase 1 Interventional

Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT07086521
View directory record Official record
Conditions
FSHD - Facioscapulohumeral Muscular Dystrophy
Interventions
ULSC, Placebo
Biological
Lead sponsor
Restem, LLC.
Industry
Eligibility
15 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 22, 2026, 6:55 PM EDT
Recruiting Phase 1 Interventional

Trial of Cell Based Therapy for DMD

NCT06692426
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
MyoPAXon, Tacrolimus
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 22, 2026, 6:55 PM EDT
Recruiting Phase 4 Interventional

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy

NCT05861986
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Months to 24 Months
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
11
States / cities
Little Rock, Arkansas • Aurora, Colorado • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 22, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

NCT02386553
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Nusinersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
0 Weeks to 6 Weeks
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
11
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 22, 2026, 6:55 PM EDT
Completed No phase listed Observational

Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD)

NCT03981289
View directory record Official record
Conditions
Limb Girdle Muscular Dystrophy, Muscular Dystrophies
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
4 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
9
States / cities
Irvine, California • Aurora, Colorado • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 22, 2026, 6:55 PM EDT